Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
IPO News

| More

Emcure Pharmaceuticals Limited files DRHP for an IPO

Posted On: 2013-07-01 22:56:27

Emcure Pharmaceuticals Limited (the "Company" or the "Issuer") has filed a draft red herring prospectus (the "DRHP") with the Securities and Exchange Board of India ("SEBI") for offering of equity shares of face value Rs. 10 each (the "Equity Shares") for cash at a price per Equity Share including a share premium to be determined through the book building process (the "Issue"). The Issue comprises a fresh issue of Equity Shares aggregating up to Rs. 3,000 million (the "Fresh Issue") and an offer for sale of up to 2,513,057 Equity Shares by certain existing shareholders of the Company.

In terms of Rule 19(2)(b)(ii) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"), the Issue is for at least 10% of the post-Issue capital where the post-Issue capital of the Company calculated at the Issue Price will be more than Rs. 40,000 million. Not more than 50% of the Issue shall be available for allocation on a proportionate basis to qualified institutional buyer ("QIB") bidders; 5% of the QIB Portion (excluding anchor investor portion) shall be available for allocation on a proportionate basis to mutual funds only, and the remainder of the QIB portion shall be available for allocation on a proportionate basis to all QIBs, including mutual funds, subject to valid bids being received at or above the Issue price. Further, not less than 15% of the Issue shall be available for allocation on a proportionate basis to non-institutional bidders and not less than 35% of the Issue shall be available for allocation to retail individual bidders, subject to valid bids being received at or above the Issue price. QIBs (other than anchor investors) and non-institutional bidders shall participate in the Issue through the application supported by blocked amount ("ASBA") process only providing the details of the bank account which will be blocked by the self certified syndicate banks to the extent of the bid amount for the same. Retail individual bidders may also participate in the Issue through the ASBA process.

The Equity Shares offered in the Issue are proposed to be listed on BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE").

The book running lead managers to the Issue are DSP Merrill Lynch Limited, IDFC Capital Limited and Morgan Stanley India Company Private Limited.

The Company is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Its core strength lies in in-house development and manufacturing of differentiated pharmaceutical products. The Company focuses its research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules, biosimilars and novel drug delivery systems. The Company commercializes its products through a combination of its own marketing and distribution infrastructure across geographies as well as relationships with multi-national pharmaceutical companies.

The Company believes its competitive advantage in the domestic market lies in its established presence in all major therapeutic areas. It has a pan India marketing and distribution presence with a field force of more than 4,800 personnel, as of March 31, 2013. The Company has a well-diversified income base in terms of geographies, therapeutic areas and business segments within the pharmaceutical industry. The Company has its own sales and marketing infrastructure in the United States through its subsidiary, Heritage. The Company also sells its portfolio of branded generic products to the rest of world. Its products are currently shipped to over 65 countries, where it has established its presence by focusing on important alliances with local and multi-national companies. The Company has subsidiaries in Brazil, Dubai, Nigeria, Singapore and South Africa and branch offices in Morocco and Russia, which play an important role in its international operations. It operates nine manufacturing facilities, eight of which are located in India and one in the United States. Several of these facilities have approvals from various regulatory bodies, including the USFDA and the UK-MHRA. These facilities are capable of producing APIs and pharmaceutical products encompassing a wide range of dosage forms including oral solids, oral liquids, soft gelatin capsules and injectables (both liquid and lyophilized). The manufacturing capability of the Company allows it to manufacture complex products, including cytotoxic products. The Company also manufactures products for certain pharmaceutical multi-national companies and the Company believes that it has emerged as a technologically dependable and quality conscious company of choice for these companies. The Company is led by highly qualified and experienced management team and the board of directors.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

HDFC updates on proposed IPO of HDFC Standard Life Insurance Company Ltd
Srei Equipment Finance plans to dilute upto 25% of its capital
Cochin Shipyard Ltd - IPO Note - Angel Broking
Security and Intelligence Services (India) Ltd - IPO Note - Angel Broking
M&M to sell part of its stake in Mahindra Logistics Ltd in IPO
Salasar Techno Engineering Ltd - IPO Note - Hem Securities Ltd
ICICI Lombard General Insurance Company Limited files DRHP for IPO
20 Microns Nano Minerals Ltd to come with SME IPO
AU Small Finance Bank Ltd - IPO Note - CSEC Research
AU Small Finance Bank - IPO Note - Sushil Finance
IPO: AU Small Finance Bank - Subscribe - IIFL
CDSL IPO evokes huge demand from investors
Ashok Leyland Ltd's subsidiary Hinduja Leyland Finance withdraws IPO
CDSL IPO subscribed 170.11 times
GTPL Hathway Ltd - IPO Note - Angel Broking
Central Depository Services Ltd - IPO Note - Angel Broking
Bharat Road Network Ltd receives observation letter from SEBI for the DRHP
PSP Projects Limited - IPO Note - Angel Broking
India Grid Trust - IPO Note - Angel Broking
Hudco Ltd - Focus on Housing and Urban Infrastructure Finance in India: Angel Broking
S Chand and Company Limited IPO garners subscription of 59.49 times
S.Chand & Company Ltd - Providing the syllabus for growth: Angel Broking
S. Chand and Company Limited - IPO Note - Sushil Finance
Shankara Building Products Limited IPO to close for subscription today
CL Educate Limited receives subscription of 1.90 times
Escorp Asset Management IPO to open for subscription on Mar 31, 2017
Avenue Supermarts Limited to list today
Chemcrux Enterprises Ltd SME IPO gets huge over subscription
Shankara Building Products Limited - Thrust on retail to boost potential - Angel Broking
CL Educate Limited - Preparing for the big Test: Angel Broking
Optimus Finance Ltd announces IPO of wholly owned subsidiary
Gitanjali Brands Limited files DRHP with SEBI, BSE and NSE
Jagran Prakashan Limited announces fixing of IPO price by Music Broadcast Ltd at Rs. 333
Avenue Supermarts Limited - A retailer with a growth appetite - Angel Broking
Avenue Supermarts Limited - IPO Note - Sushil Finance
Music Broadcast Limited - IPO Note - Sushil Finance
Avenue Supermarts Limited - A retailer with a growth appetite: Angel Broking
Music Broadcast Limited fixes IPO price band as Rs. 325 to Rs. 333
Music Broadcast Limited IPO to open on Mar 6, 2017
India Finsec Ltd arm IFL Enterprises Limited gets approval fo Public Issue of equity shares on SME Platform of BSE Limited
SREI Infrastructure Finance Ltd's arm Bharat Road Network Limited Files DRHP with SEBI for IPO
GlobalSpace Technologies Limited plans SME IPO, files papers with BSE
Nakshatra World Limited, wholly owned subsidiary of Gitanjali Gems Ltd to raise funds through IPO
Jagran Prakashan Ltd arm Music Broadcast Ltd files DRHP with SEBI for IPO
Majestic Research Services and Solutions Ltd receives approval from ROC for RHP filed for Further Public Issue
GNA Axles Limited - IPO Note Attractive on Valuations: Subscribe - Angel Broking
L&T Technology Services Limited - Issue competitively priced - Subscribe - Angel Broking
IRB Infrastructure Developers Ltd arm files for IPO of units
RBL Bank - IPO Note - SUBSCRIBE - Long-term Play on Strong Growth Potential - Reliance Securities
RBL Bank - IPO Note - Strong Management at the helm of affairs - Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017